Basel, 2018-10-31 - NBE-Therapeutics was invited to present at Terrapinn's 2018 High-potency API congress
Roger Beerli, CSO of NBE-Therapeutics, was invited to provide an update on NBE-Therapeutics ADC development activities at Terrapinn's High-potency API congress, which is part of the 2018 Festival of Biologics
NBE-Therapeutics was invited for a presentation at Terrapinn's 2018 Festival of Biologics, which includes the European Antibody Congress, the World Immunotherapy congress and the High-potency API congress. Roger's presentation took place in the "ADCs and new molecules" stream of the High-potency API congress on Wednesday, Oct 31, 11:20 a.m. and was entitled "Anthracycline-based antibody drug conjugates with potent immune-stimulatory functions". In his presentation, Roger presented the concept of the strong immune-stimulatory function of NBE's anthracycline-based ADC platform that can trigger a long-lasting anti-tumor immunity in syngeneic mouse tumor models.
Recent news feed
RSS feed from: